U.S. News & World Report has published its inaugural ratings for telehealth platforms specializing in GLP-1 weight-loss medications. This new resource assesses 20 online providers based on clinical support, insurance transparency, and user feedback to assist patients navigating a crowded digital health market.
The ratings focus exclusively on platforms offering FDA-approved medications such as semaglutide, tirzepatide, and orforglipron. Platforms that distribute only compounded GLP-1 drugs were excluded from the analysis due to safety concerns. Experts emphasize that these services should act as a supplement to in-person medical care rather than a complete replacement for traditional physician oversight.
Eleven companies secured top spots in the evaluation, including Amazon One Medical, Noom, Ro, and WeightWatchers. The methodology relied on a 5-point scale across six core categories, incorporating direct insights from over 1,200 active users. While patient satisfaction levels remain high, the report serves as a guide for those managing complex insurance requirements and varying standards of clinical monitoring.
Health analysts identify the expansion of GLP-1 treatments as a primary public health trend for 2026. As demand increases, the availability of clear, vetted information becomes a critical tool for consumers. Patients are encouraged to maintain communication with their primary care physicians to ensure these treatments align with their broader health objectives.